Enanta Pharmaceuticals Inc.

ENTA Nasdaq SEC CIK 1177648
Follow Enanta Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2026 USD · US GAAP
Revenue, last quarter $12.9M −14.9% vs same quarter last year
Net income −$23.7M −26.8% vs same quarter last year
EPS, diluted -
Operating cash flow −$13.7M −111.6% vs same quarter last year
Revenue by quarter
$17M
$14.9M
$18.3M
$15.1M
$18.6M
$17.2M
$14.4M
$12.9M
Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 Q4 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$200M−$100M$0$100M$200M$300MFY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearRevenueNet income
FY26$63M−$68.2M
FY25$65.3M−$81.9M
FY24$67.6M−$116M
FY23$79.2M−$133.8M
FY22$86.2M−$121.8M
FY21$97.1M−$79M
FY20$122.5M−$36.2M
FY19$205.2M$46.4M
FY18$206.6M$72M
FY17$102.8M$17.7M
FY16$88.3M$21.7M
FY15$160.9M$79M
FY14$47.7M$34.4M
FY13$32.1M-
FY12$41.7M$21.4M
MarginsShare of revenue
  • Operating margin
  • Net margin
−200%−100%0%100%FY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearOperating marginNet margin
FY26−99%−108.3%
FY25−130.7%−125.4%
FY24−179.9%−171.6%
FY23−173.2%−169%
FY22−143.7%−141.3%
FY21−112.9%−81.4%
FY20−34%−29.5%
FY1917.9%22.6%
FY1842.7%34.8%
FY1723.9%17.2%
FY1634.9%24.5%
FY1577.2%49.1%
FY1439.8%72.1%
FY1328.2%-
FY1251%51.3%
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0$50M$100MFY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearFree cash flow
FY26−$42.8M
FY25−$32.2M
FY24−$96.7M
FY23−$112.2M
FY22−$86.9M
FY21−$70.7M
FY20$5.6M
FY19$66M
FY18$26.2M
FY17$50.1M
FY16$31.1M
FY15$74.3M
FY14$19.2M
FY13$10M
FY12$22.4M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Enanta Pharmaceuticals
  • Healthcare median
−200%−100%0%100%FY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearEnanta PharmaceuticalsHealthcare median
FY26−108.3%−11.1%
FY25−125.4%−30.6%
FY24−171.6%−47%
FY23−169%−58%
FY22−141.3%−80.4%
FY21−81.4%−71.9%
FY20−29.5%−62.2%
FY1922.6%−46.3%
FY1834.8%−49.6%
FY1717.2%−45.9%
FY1624.5%−36%
FY1549.1%−38.4%
FY1472.1%−35.5%
FY13-−37.1%
FY1251.3%−29.1%